- Home
- OABI vs ALEC Comparison
OABI vs ALEC Comparison
Compare OABI & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- ALEC
- Stock Information
- Founded
- OABI 2012
- ALEC 2013
- Country
- OABI United States
- ALEC United States
- Employees
- OABI N/A
- ALEC N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OABI Health Care
- ALEC Health Care
- Exchange
- OABI Nasdaq
- ALEC Nasdaq
- Market Cap
- OABI 459.1M
- ALEC 454.5M
- IPO Year
- OABI N/A
- ALEC 2019
- Fundamental
- Price
- OABI $3.85
- ALEC $3.76
- Analyst Decision
- OABI Strong Buy
- ALEC Strong Buy
- Analyst Count
- OABI 4
- ALEC 5
- Target Price
- OABI $9.00
- ALEC $20.67
- AVG Volume (30 Days)
- OABI 509.5K
- ALEC 749.0K
- Earning Date
- OABI 11-12-2024
- ALEC 11-06-2024
- Dividend Yield
- OABI N/A
- ALEC N/A
- EPS Growth
- OABI N/A
- ALEC N/A
- EPS
- OABI N/A
- ALEC N/A
- Revenue
- OABI $20,409,000.00
- ALEC $61,508,000.00
- Revenue This Year
- OABI N/A
- ALEC N/A
- Revenue Next Year
- OABI $71.78
- ALEC $118.87
- P/E Ratio
- OABI N/A
- ALEC N/A
- Revenue Growth
- OABI N/A
- ALEC N/A
- 52 Week Low
- OABI $3.56
- ALEC $3.49
- 52 Week High
- OABI $6.72
- ALEC $8.90
- Technical
- Relative Strength Index (RSI)
- OABI 40.94
- ALEC 35.09
- Support Level
- OABI $3.62
- ALEC $3.57
- Resistance Level
- OABI $4.19
- ALEC $6.14
- Average True Range (ATR)
- OABI 0.23
- ALEC 0.48
- MACD
- OABI -0.06
- ALEC -0.20
- Stochastic Oscillator
- OABI 18.40
- ALEC 10.19
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.